CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 47 enrolled
Drug / intervention
Cholecalciferoldrug
Likely dose
Cholecalciferol 4000 IUfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05347082
NCT05347082N/ACompleted
CompareCT.gov

Resolution of Hyperparathyroidism With High-dose Vitamin D Improves Osteoporosis in Multi-treated Postmenopausal Women

Hospital Regional 1o de Octubre·interventional·Posted Apr 26, 2022·Updated May 6, 2022

In Brief

A clinical study evaluating Cholecalciferol for Postmenopausal Osteoporosis and 4 related conditions. Completed, enrolled 47 participants across 1 site.

Detailed Summary

Recently, an increase in the prevalence of hyperparathyroidism and hypovitaminosis D in postmenopause women has been occurring in Mexico and the world. Chronic exposure to the parathyroid hormone (PTH) is catabolic for the bone, worsening the state of osteoporosis. However, it is unclear whether these conditions could significantly improve bone mineral density (BMD). In the present work, it was shown that the resolution of hyperparathyroidism in postmenopausal women improves osteoporosis.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPostmenopausal Osteoporosis, Postmenopause, Hyperparathyroidism, Secondary, Hypovitaminosis D, Hyperparathyroidism, Primary
CountriesMexico
CollaboratorsUniversidad Nacional Autonoma de Mexico, National Polytechnic Institute, Mexico

Timeline

N/ACompletedFinished
20222023202420252026
First PostedApr 26, 2022
Enrollment StartApr 29, 2021
Primary CompletionDec 29, 2021
Study CompletionFeb 20, 2022
TodayJul 2, 2026
Enrollment to primary: 8 monthsPosted 4.2 years ago

Interventions

Cholecalciferoldrug

Tablets of 4000 IU